Evidence map›Paper›PMID 26923718›Full record

ReviewJournal of molecular medicine (Berlin, Germany)2016

Biological and pathological activities of interleukin-22.

Mirna Perusina Lanfranca, Yanwei Lin, Jingyuan Fang, Weiping Zou, Timothy Frankel

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of molecular medicine (Berlin, Germany), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 1 pooled it
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 1 synthesis or guideline pooled it, 135 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. IL-22 synergizes with IL-17 to promote mucosal inflammation and bone loss.Journal of immunology (Baltimore, Md. : 1950) · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. The role of IL-22 in cancer.Medical oncology (Northwood, London, England) · 2024
    Review
  18. Review
  19. [Old and New Biologics and Small Molecules in Inflammatory Bowel Disease: Anti-interleukins].The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2024
    Review
  20. Review

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Mirna Perusina LanfrancaDepartment of Surgery, University of Michigan School of Medicine, 109 Zina Pitcher Place, Ann Arbor, MI, 48109, USA.
Yanwei LinDepartment of Surgery, University of Michigan School of Medicine, 109 Zina Pitcher Place, Ann Arbor, MI, 48109, USA.
Jingyuan FangDivision of Gastroenterology and Hepatology, Renji Hospital, School of Medicine, Shanghai Jiao-Tong University, Shanghai, 200001, China.
Weiping ZouDepartment of Surgery, University of Michigan School of Medicine, 109 Zina Pitcher Place, Ann Arbor, MI, 48109, USA. wzou@med.umich.edu.
Timothy FrankelDepartment of Surgery, University of Michigan School of Medicine, 109 Zina Pitcher Place, Ann Arbor, MI, 48109, USA. timofran@med.umich.edu.
University of Michigan–Ann Arbor · USShanghai Jiao Tong University · CN

Funding

Immune Regulation in the Microenvironment of Oropharyngeal CancerR01CA171306 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ZOU, WEIPING · 2013 to 2017
$2.8M
Effector T Cell Trafficking in Ovarian CancerR01CA190176 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ZOU, WEIPING · 2015 to 2019
$2.6M
MDSCs in Ovarian CancerR01CA193136 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ZOU, WEIPING · 2015 to 2019
$2.5M
Memory T Cells in the Tumor MicroenvironmentR01CA152470 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ZOU, WEIPING · 2011 to 2015
$1.9M
NCI NIH HHS R01 CA152470NCI NIH HHS R01 CA171306NCI NIH HHS R01 CA190176NCI NIH HHS R01 CA193136
6 · The paper itself

Abstract

Interleukin (IL)-22, a member of the IL-10 family, is a cytokine secreted by several types of immune cells including IL-22(+)CD4(+) T cells (Th22) and IL-22 expressing innate leukocytes (ILC22). Recent studies have demonstrated that IL-22 is a key component in mucosal barrier defense, tissue repair, epithelial cell survival, and proliferation. Furthermore, accumulating evidence has defined both protective and pathogenic properties of IL-22 in a number of conditions including autoimmune disease, infection, and malignancy. In this review, we summarize the expression and signaling pathway and functional characteristics of the IL-22 and IL-22 receptor axis in physiological and pathological scenarios and discuss the potential to target IL-22 signaling to treat human diseases.

Indexed as

AnimalsAutoimmune DiseasesAutoimmunityCell Transformation, NeoplasticHumansInflammationInterleukin-22InterleukinsNeoplasmsReceptors, InterleukinSignal TransductionInterleukin-22interleukin-22 receptorInterleukinsReceptors, InterleukinAutoimmuneCancerIL-22IL-22BPIL-22RILC22InfectionT cellTh22

Identifiers

PMID26923718
PMCPMC4860114
OpenAlexW2283396335

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.